Targeting PCSK9 for Therapeutic Gains

详细信息    查看全文

• 作者：Michael D. Shapiro (1)
  Sergio Fazio (1)
  Hagai Tavori (1)
  
  1. The Knight Cardiovascular Institute ; Center for Preventive Cardiology ; Oregon Health and Science University ; 3181 S.W. Sam Jackson Park Road ; Portland ; OR ; USA
  
• 关键词：Proprotein convertase subtilisin kexin 9 ; Low ; density lipoprotein receptor ; Low ; density lipoprotein ; Lipoprotein (a) ; Triglycerdies ; Pleiotropic effects
• 刊名：Current Atherosclerosis Reports
• 出版年：2015
• 出版时间：April 2015
• 年：2015
• 卷：17
• 期：4
• 全文大小：925 KB
• 参考文献：1. Abifadel, M (2014) Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs. Curr Atheroscler Rep 16: pp. 439 p://dx.doi.org/10.1007/s11883-014-0439-8" target="_blank" title="It opens in new window">CrossRef
  2. Abifadel, M (2003) Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 34: pp. 154-6 p://dx.doi.org/10.1038/ng1161" target="_blank" title="It opens in new window">CrossRef
  3. Zhang, DW (2007) Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J Biol Chem 282: pp. 18602-12 p://dx.doi.org/10.1074/jbc.M702027200" target="_blank" title="It opens in new window">CrossRef
  4. Cohen, J (2005) Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet 37: pp. 161-5 p://dx.doi.org/10.1038/ng1509" target="_blank" title="It opens in new window">CrossRef
  5. Cohen, JC (2006) Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 354: pp. 1264-72 p://dx.doi.org/10.1056/NEJMoa054013" target="_blank" title="It opens in new window">CrossRef
  6. Hooper, AJ (2007) The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population. Atherosclerosis 193: pp. 445-8 p://dx.doi.org/10.1016/j.atherosclerosis.2006.08.039" target="_blank" title="It opens in new window">CrossRef
  7. Fasano, T (2007) A novel loss of function mutation of PCSK9 gene in white subjects with low-plasma low-density lipoprotein cholesterol. Arterioscler Thromb Vasc Biol 27: pp. 677-81 p://dx.doi.org/10.1161/01.ATV.0000255311.26383.2f" target="_blank" title="It opens in new window">CrossRef
  8. Dadu, RT, Ballantyne, CM (2014) Lipid lowering with PCSK9 inhibitors. Nat Rev Cardiol 11: pp. 563-75 p://dx.doi.org/10.1038/nrcardio.2014.84" target="_blank" title="It opens in new window">CrossRef
  9. Rashid, S (2014) PCSK9 promotes intestinal overproductin of triglyceride-rich apolipoprotien-B liporptoein throug both LDL-receptor dependent and independent mechanisms. Circulation 130: pp. 431-41 p://dx.doi.org/10.1161/CIRCULATIONAHA.113.006720" target="_blank" title="It opens in new window">CrossRef
  10. Levy, E (2013) PCSK9 plays a significant role in cholesterol homeostasis and lipid transport in intestinal epithelial cells. Atherosclerosis 227: pp. 297-306 p://dx.doi.org/10.1016/j.atherosclerosis.2013.01.023" target="_blank" title="It opens in new window">CrossRef
  11. May, C (2009) Proprotein convertase subtilisin kexin type 9 null mice are protected from postprandial triglyceridemia. Arterioscler Thromb Vasc Biol 29: pp. 684-90 p://dx.doi.org/10.1161/ATVBAHA.108.181586" target="_blank" title="It opens in new window">CrossRef
  12. Raal, FJ (2014) Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials. J Am Coll Cardiol 63: pp. 1278-88 p://dx.doi.org/10.1016/j.jacc.2014.01.006" target="_blank" title="It opens in new window">CrossRef
  13. Gaudet, D (2014) Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150聽mg every two weeks dosing from phase 2 trials). Am J Cardiol 114: pp. 711-5 p://dx.doi.org/10.1016/j.amjcard.2014.05.060" target="_blank" title="It opens in new window">CrossRef
  14. Raal, F.J., et al., Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. The Lancet, (0). / This study demonstrated the potential utility of PCSK9 inhibition in patients with genetically proven homozygous familial hypercholesterolemia. On average, evolocumab lowered LDL-C by 31% versus placebo. The results established a clear relationship between the underlying LDL receptor mutation (defective vs. null) and LDL-C reduction with evolocumab.
  15. Stein, EA (2013) Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation 128: pp. 2113-20 p://dx.doi.org/10.1161/CIRCULATIONAHA.113.004678" target="_blank" title="It opens in new window">CrossRef
  16. Cully, M (2013) Dyslipidaemia: RNAi targeting PCSK9 decreases lipid levels in a human trial. Nat Rev Cardiol 10: pp. 682 p://dx.doi.org/10.1038/nrcardio.2013.163" target="_blank" title="It opens in new window">CrossRef
  17. Schwartz, GG (2014) Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial. Am Heart J 168: pp. 682-689.e1 p://dx.doi.org/10.1016/j.ahj.2014.07.028" target="_blank" title="It opens in new window">CrossRef
  18. Roth, E.M., et al., A 24-Week study of Alirocumab as Monotherapy versus ezetimibe: the first phase 3 data of a proprotein convertase subtilisin/kexin type 9 inhibitor. J Am Coll Cardiol, 2014. 63(12_S).
  19. Kastelein, JP (2014) Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: design and rationale of the ODYSSEY FH studies. Cardiovasc Drugs Ther 28: pp. 281-9 p://dx.doi.org/10.1007/s10557-014-6523-z" target="_blank" title="It opens in new window">CrossRef
  20. Ginsberg, H.N., et al., ODYSSEY HIGH FH: Efficacy and Safety of Alirocumab in Patients With Severe Heterozygous Familial Hypercholesterolemia, in Circulation. 2014.
  21. Robinson, J., et al., Long-term safety, tolerability and efficacy of alirocumab versus placebo in high cardiovascular risk patients: first results from the ODYSSEY LONG TERM study in 2,341 patients Eur Heart J, 2014. 35. / This study demonstrated the long-term (52聽weeks) tolerability and efficacy of alirocumab. A post-hoc analysis suggested a statistically significant 54聽% reduction in major adverse cardiovascular events with alirocumab (p鈥?lt;鈥?.01). The investigators also confirmed the safety in subjects achieving an LDL-C <25聽mg/dL.
  22. Robinson, J., et al., Long-term Safety, Tolerability and Efficacy of Alirocumab versus Placebo in 2,341 High Cardiovascular Risk Patients: ODYSSEY LONG TERM Circulation, 2014. 130. / This study demonstrated the long-term (52聽weeks) tolerability and efficacy of alirocumab. A post-hoc analysis suggested a statistically significant 54聽% reduction in major adverse cardiovascular events with alirocumab (p鈥?lt;鈥?.01). The investigators also confirmed the safety in subjects achieving an LDL-C <25聽mg/dL.
  23. Moriarty PM et al. ODYSSEY ALTERNATIVE: efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody, alirocumab, versus ezetimibe, in patients with statin intolerance as defined by a placebo run-in and statin rechallenge arm. Circulation. 2014;130.
  24. Moriarty, PM (2014) Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial. J Clin Lipidol 8: pp. 554-61 p://dx.doi.org/10.1016/j.jacl.2014.09.007" target="_blank" title="It opens in new window">CrossRef
  25. Guyton, JR (2014) An assessment by the Statin Intolerance Panel: 2014 update. J Clin Lipidol 8: pp. S72-81 p://dx.doi.org/10.1016/j.jacl.2014.03.002" target="_blank" title="It opens in new window">CrossRef
  26. Bays H et al. Efficacy and safety of combining alirocumab with atorvastatin or rosuvastatin versus statin intensification or adding ezetimibe in high cardiovascular risk patients: ODYSSEY OPTIONS I and II. Circulation. 2014;130.
  27. Robinson, JG (2014) Efficacy and safety of alirocumab as add-on therapy in high-cardiovascular-risk patients with hypercholesterolemia not adequately controlled with atorvastatin (20 or 40聽mg) or rosuvastatin (10 or 20聽mg): design and rationale of the ODYSSEY OPTIONS studies. Clin Cardiol 37: pp. 597-604 p://dx.doi.org/10.1002/clc.22327" target="_blank" title="It opens in new window">CrossRef
  28. Colhoun, H (2014) Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials. BMC Cardiovasc Disord 14: pp. 121 p://dx.doi.org/10.1186/1471-2261-14-121" target="_blank" title="It opens in new window">CrossRef
  29. Kereiakes DJ et al. Efficacy and dafety of alirocumab in high cardiovascular risk patients with suboptimally controlled hypercholesterolemia on maximally tolerated doses of statins: the ODYSSEY COMBO I study. Circulation. 2014;130.
  30. Cannon CP et al. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated daily statin: results from the ODYSSEY COMBO II study. Eur Heart J. 2014;35.
  31. Koren, MJ (2014) Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. J Am Coll Cardiol 63: pp. 2531-40 p://dx.doi.org/10.1016/j.jacc.2014.03.018" target="_blank" title="It opens in new window">CrossRef
  32. Blom, DJ (2014) A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 370: pp. 1809-19 p://dx.doi.org/10.1056/NEJMoa1316222" target="_blank" title="It opens in new window">CrossRef
  33. Robinson, JG (2014) Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on ldl-c lowering in patients with hypercholesterolemia: The laplace-2 randomized clinical trial. JAMA 311: pp. 1870-83 p://dx.doi.org/10.1001/jama.2014.4030" target="_blank" title="It opens in new window">CrossRef
  34. Stroes, E (2014) Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol 63: pp. 2541-8 p://dx.doi.org/10.1016/j.jacc.2014.03.019" target="_blank" title="It opens in new window">CrossRef
  35. Raal, F.J., et al., PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. The Lancet, (0).
  36. Weinreich, M, Frishman, WH (2014) Antihyperlipidemic therapies targeting PCSK9. Cardiol Rev 22: pp. 140-6 p://dx.doi.org/10.1097/CRD.0000000000000014" target="_blank" title="It opens in new window">CrossRef
  37. Gumbiner BM et al. Effects of 12 weeks of treatment with RN316 (PF-04950615), a humanized IgG2螖a monoclonal antibody binding proprotein convertase subtilisin kexin type 9, in hypercholesterolemic subjects on high and maximal dose statins. Circulation. 2012;126.
  38. Ballantyne, C.M., et al., Efficacy and safety of Bococizumab (RN316/PF-04950615), a monoclonal antibody against proprotein convertase Subtilisin/Kexin type 9 in statin-treated Hypercholesterolemic subjects: results from a randomized, placebo-controlled, dose-ranging study (NCT: 01592240). Journal of the American College of Cardiology, 2014. 63(12_S).
  39. McKenney, JM (2012) Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol 59: pp. 2344-53 p://dx.doi.org/10.1016/j.jacc.2012.03.007" target="_blank" title="It opens in new window">CrossRef
  40. Roth, EM (2012) Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med 367: pp. 1891-900 p://dx.doi.org/10.1056/NEJMoa1201832" target="_blank" title="It opens in new window">CrossRef
  41. Stein, E (2012) Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet 380: pp. 29-36 p://dx.doi.org/10.1016/S0140-6736(12)60771-5" target="_blank" title="It opens in new window">CrossRef
  42. Giugliano, RP (2012) Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet 380: pp. 2007-17 p://dx.doi.org/10.1016/S0140-6736(12)61770-X" target="_blank" title="It opens in new window">CrossRef
  43. Koren, MJ (2012) Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet 380: pp. 1995-2006 p://dx.doi.org/10.1016/S0140-6736(12)61771-1" target="_blank" title="It opens in new window">CrossRef
  44. Raal, F (2012) Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the reduction of LDL-C with PCSK9 inhibition in heterozygous familial hypercholesterolemia disorder (RUTHERFORD) randomized trial. Circulation 126: pp. 2408-17 p://dx.doi.org/10.1161/CIRCULATIONAHA.112.144055" target="_blank" title="It opens in new window">CrossRef
  45. Sullivan, D (2012) Effect of a monoclonal antibody to pcsk9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the gauss randomized trial. JAMA 308: pp. 2497-506 p://dx.doi.org/10.1001/jama.2012.25790" target="_blank" title="It opens in new window">CrossRef
  46. Stein, EA (2012) Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 366: pp. 1108-18 p://dx.doi.org/10.1056/NEJMoa1105803" target="_blank" title="It opens in new window">CrossRef
  47. Dias, CS (2012) Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins. J Am Coll Cardiol 60: pp. 1888-98 p://dx.doi.org/10.1016/j.jacc.2012.08.986" target="_blank" title="It opens in new window">CrossRef
  48. Group, HTC (2013) HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 34: pp. 1279-91 p://dx.doi.org/10.1093/eurheartj/eht055" target="_blank" title="It opens in new window">CrossRef
  49. Boden, W (2011) Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 365: pp. 2255-67 p://dx.doi.org/10.1056/NEJMoa1107579" target="_blank" title="It opens in new window">CrossRef
  50. Albers, JJ (2013) Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (atherothrombosis intervention in metabolic syndrome with Low HDL/high triglyceride and impact on global health outcomes). J Am Coll Cardiol 62: pp. 1575-9 p://dx.doi.org/10.1016/j.jacc.2013.06.051" target="_blank" title="It opens in new window">CrossRef
  51. Poirier, S (2008) The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2. J Biol Chem 283: pp. 2363-72 p://dx.doi.org/10.1074/jbc.M708098200" target="_blank" title="It opens in new window">CrossRef
  52. Roubtsova, A (2011) Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue. Arterioscler Thromb Vasc Biol 31: pp. 785-91 p://dx.doi.org/10.1161/ATVBAHA.110.220988" target="_blank" title="It opens in new window">CrossRef
  53. Zaid, A (2008) Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration. Hepatology 48: pp. 646-54 p://dx.doi.org/10.1002/hep.22354" target="_blank" title="It opens in new window">CrossRef
  54. Rashid, S (2005) Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc Natl Acad Sci U S A 102: pp. 5374-9 p://dx.doi.org/10.1073/pnas.0501652102" target="_blank" title="It opens in new window">CrossRef
  55. Fitzgerald, K (2014) Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. Lancet 383: pp. 60-8 p://dx.doi.org/10.1016/S0140-6736(13)61914-5" target="_blank" title="It opens in new window">CrossRef
  56. Tavori, H (2013) Serum proprotein convertase subtilisin/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation. Circulation 127: pp. 2403-13 p://dx.doi.org/10.1161/CIRCULATIONAHA.113.001592" target="_blank" title="It opens in new window">CrossRef
  57. Kosenko, T (2013) Low density lipoprotein binds to proprotein convertase subtilisin/kexin type-9 (PCSK9) in human plasma and inhibits PCSK9-mediated low density lipoprotein receptor degradation. J Biol Chem 288: pp. 8279-88 p://dx.doi.org/10.1074/jbc.M112.421370" target="_blank" title="It opens in new window">CrossRef
  58. Sun, H (2012) Proprotein convertase subtilisin/kexin type 9 interacts with apolipoprotein B and prevents its intracellular degradation, irrespective of the low-density lipoprotein receptor. Arterioscler Thromb Vasc Biol 32: pp. 1585-95 p://dx.doi.org/10.1161/ATVBAHA.112.250043" target="_blank" title="It opens in new window">CrossRef
  59. Stein, EA (2012) Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation 126: pp. 2283-92 p://dx.doi.org/10.1161/CIRCULATIONAHA.112.104125" target="_blank" title="It opens in new window">CrossRef
  60. Raal, FJ, Santos, RD (2012) Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. Atherosclerosis 223: pp. 262-8 p://dx.doi.org/10.1016/j.atherosclerosis.2012.02.019" target="_blank" title="It opens in new window">CrossRef
  61. Tavori, H (2013) Loss of plasma proprotein convertase subtilisin/kexin 9 (PCSK9) after lipoprotein apheresis. Circ Res 113: pp. 1290-5 p://dx.doi.org/10.1161/CIRCRESAHA.113.302655" target="_blank" title="It opens in new window">CrossRef
  
• 刊物主题：Angiology; Cardiology;
• 出版者：Springer US
• ISSN：1534-6242

文摘

Even though it is only a little over a decade from the discovery of proprotein convertase subtilisin/kexin type 9 (PCSK9) as a plasma protein that associates with both hypercholesterolemia and low cholesterol syndromes, a rich literature has developed describing its unique physiology and the impact of antagonism of this molecule on cholesterol metabolism for therapeutic purposes. Indeed, the PCSK9 story is unfolding rapidly, with many answers and more questions. This review summarizes the most recent data from phase II/III clinical trials of PCSK9 inhibition with the three leading antibodies, highlights the clinical significance of the ongoing studies, and suggests future areas of investigation based on recent basic science discoveries on the physiology of PCSK9.